Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Share Talk Bulletin Board Heroes, Monday 5th October 2020
TPI provides its latest research note on Avacta Group Plc (AVCT.L).
Avacta released its unaudited interim results for the six-month period ended 30 June 2020 on Monday. They detailed a period of significant advancement for the Group despite the restrictions placed upon it
Avacta Group plc (AVCT.L) Launch of SARS-CoV-2 BAMSTM Research Test
Affimer-based research assay launched alongside performance data published by Bruker
Share Talk Bulletin Board Heroes, Wednesday 30th September 2020
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Share Talk Weekly Stock Market News, Sunday 20th September 2020
Welcome to the Share Talk Weekly Newsletter as we look back at the week that was.
Avacta Group PLC (AVCT.L) Notice of Results and Investor Presentation
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, will announce its unaudited interim results for the 6 months ended 30 June 2020 on Monday, 28 September
Share Talk Bulletin Board Heroes, Thursday 10th September 2020
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
TPI provides its latest research note on Avacta Group Plc (AVCT.L).
Avacta has announced that it will launch a high-performance Affimer research enzyme-linked immunosorbent assay (‘ELISA’) test in order to support global research efforts into the coronavirus that causes COVID-19.
Share Talk Weekly Stock Market News, Sunday 6th September 2020
Another week of more highs than lows across the small-cap markets, we are losing count of companies we are highlighting that hit a new 52 wk high.
TPI provides its latest research note on Avacta Group plc (AVCT.L).
Recognising that manufacturing capacity now represents the key challenge it faces in the global provision of its innovative, rapid, saliva-based SARS-CoV-2 antigen test that is being developed with Cytiva (formerly GE Healthcare
Share Talk Bulletin Board Heroes, Thursday 3rd September 2020
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
